SymbioCellTech
Business Services · Utah, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
615 S Arapeen Dr Ste 210, Salt Lake City...Phone Number
(801) 503-3990Website
www.symbiocelltech.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About SymbioCellTech
SymbioCellTech is focused on developing innovative therapies for Type 1 Diabetes, aiming to eliminate the need for daily insulin injections and reduce complications associated with the disease. Their flagship product, Neo-Islets, offers a next-generation solution that does not rely on immuno-suppressive agents. The company targets individuals suffering from Type 1 Diabetes, particularly the 16 million people affected in the United States. Recognized for their advancements, they were awarded the American Diabetes Association's Innovation Challenge Award in 2024.Explore more
SymbioCellTech Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SymbioCellTech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
SymbioCellTech, which may be a good buyer, showed buying intent in Masked Content Topic
Check if SymbioCellTech has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once SymbioCellTech has new funding data
Click to see if SymbioCellTech had a recent Job posting/layoffs
Product Launch: Get notified when SymbioCellTech launches new products
Check out if SymbioCellTech is spiking on competitors!
Earning: See what the market has to say on SymbioCellTech recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at SymbioCellTech
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to SymbioCellTech
Compare insights from companies similar to SymbioCellTech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
SymbioCellTech
<$5M
1-10
Private
<$5M
2006
CW
Christof WestenfelderCEO, President and Founder of SymbioCellTech, LLC
Company Profile Activity
Activity Insights
SymbioCellTech is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
SymbioCellTech is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SymbioCellTech.
SymbioCellTech financials insights
Gather financial insights about SymbioCellTech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$2.6M
2016
Private Equity
$1.9M
SymbioCellTech Tech Stack
A closer look at the technologies used by SymbioCellTech
SymbioCellTech News & Media
Novel Biotherapy for Type I Diabetes Presented at This Year’s American Diabetes Association Meeting
SymbioCellTech’s “Neo-Islet” technology, a minimally invasive, economical, and safe Stem Cell-enabled functional Cure for T1DM without immunosuppressive drugs. SALT LAKE CITY, UT, USA, September 6, 2023 /EINPresswire.com/ -- SymbioCellTech (SCT), the …Less Waste, More Doses, No Anti-Rejection Drugs: SymbioCellTech NEO-ISLETS(TM) Utilization of Donor Organs, Tissue
SymbioCellTech Shares Breakthrough Data on Impact of Novel Human NEO-ISLETS(TM) in the Efficient Utilization of Currently Discarded Tissues SALT LAKE CITY, UT, USA, August 24, 2023 /EINPresswire.com/ -- BACKGROUND: DIABETES TREATMENT BEYOND INSULIN …SymbioCellTech Demonstrates Preclinical Efficacy of Proprietary and Novel Human Neo-Islets™ Technology in STZ-Diabetic NOD-SCID Mice
Clinically relevant model validates Neo-Islets™ as a durable and potentially curative therapy for Type 1 Diabetes that does not require toxic anti-rejection drugsVirbac and SymbioCellTech Sign Exclusive Option Agreement to Develop Novel Technology for Treatment of Type 1 Diabetes in Companion Animals
SymbioCellTech, LLC (SCT), a biotechnology company in Salt Lake City, pioneering stem cell therapy for diabetes, today announced they have entere ...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SymbioCellTech
Sign Up For FreeTo access detailed company insights
SymbioCellTech is focused on developing innovative therapies for Type 1 Diabetes, aiming to eliminate the need for daily insulin injections and reduce complications associated with the disease. Their flagship product, Neo-Islets, offers a next-generation solution that does not rely on immuno-suppressive agents. The company targets individuals suffe... Read More
